The U.S. obesity rate dropped as use of GLP-1 <a href="https://healthylife7.com/the-evidence-against-10000-daily-steps-for-weight-loss/" title="The Evidence Against 10,000 Daily Steps for Weight Loss“>weight loss drugs surged.A Gallup survey finds the use of GLP-1 weight loss drugs at a new high even as the U.S. obesity rate shows a ‘meaningful’ decline. (U.S. News and World Report)
Direct-to-consumer telehealth companies are prescribing GLP-1 weight loss drugs at high rates, often overlooking obesity care measures.The Journal of the American Medical Association found that 45 of 49 sites wrote a prescription for patients. (STAT News)
The Food and Drug Administration’s pace of approvals has held up despite staff cuts, with 23 novel drugs cleared by June — the most since 2023.There’s an answer emerging on the multibillion-dollar question of whether the Trump administration’s gutting of FDA staff in April 2025 would slow down drug approvals. (Endpoints News)
The influencer-driven craze for peptides – the heavily hyped but loosely regulated proteins — may be turning into an unexpected bonanza for Chinese manufacturers of fentanyl precursors.The biohackers, fitness enthusiasts and others chasing promises of anti-aging and other health benefits often have no idea who they’re buying from. (Axios)
Europe is rewriting its public procurement rules in 2026, giving it the opportunity to create a common standard for policies, specifically surrounding “green” medicine.The industry is producing the same emissions that are increasing the demand for care and harming patient health. (Euractive)
To read yesterday’s edition of Five things for pharma marketers to know, click here
